Question 1

Has Medhat Osman, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $2,153,022 in general payments to Medhat Osman, MD across 426 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Medhat Osman, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Medhat Osman, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Novartis	35	$1,295,826
Blue Earth Diagnostics	71	$344,455
Progenics Pharmaceuticals, Inc.	268	$322,010
Eli Lilly	4	$79,231
GE HealthCare	14	$39,374
E.r. Squibb & Sons, L.L.C.	1	$37,150
Bayer	12	$18,700
Lantheus Medical Imaging, Inc.	10	$11,092
Advanced Accelerator Applications	2	$3,250
Telix Pharmaceuticals	7	$1,870
Curium US LLC	1	$51
Abiomed	1	$14

Medhat Osman, MD

Payments from drug & device makers

Who reported the general payments

What the payments were tied to

How this compares

Medicare billing

Other nuclear medicine in St Louis